{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:55:37Z","timestamp":1791212137147,"version":"4.1.0"},"reference-count":215,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inflammatory bowel diseases (IBDs), including Crohn\u2019s disease and ulcerative colitis, are immune-mediated disorders characterized by chronic gastrointestinal inflammation and a broad spectrum of extraintestinal manifestations. Among these, dermatological manifestations significantly impact patients\u2019 quality of life (QoL), presenting as conditions linked to IBD itself or IBD-related medical therapy. This comprehensive review underscores the relationship between IBD and cutaneous manifestations, with particular emphasis on erythema nodosum, pyoderma gangrenosum, Sweet syndrome, and hidradenitis suppurativa, alongside autoimmune conditions like psoriasis and vitiligo. The influence of biologic therapies, including both paradoxical skin reactions mimicking extraintestinal manifestations and nonspecific rashes, is also discussed, with a focus on the pathophysiological mechanisms and therapeutic approaches. Emerging evidence highlights the bidirectional interplay of gut-skin axis, with shared genetic, microbial, and immune pathways. Special considerations, such as pregnancy-related dermatoses, are included to provide a holistic view of this complex relationship. Improved comprehension of these manifestations not only emphasizes the necessity for interdisciplinary care, but also informs tailored therapies to address systemic inflammation while minimizing dermatological complications. This update offers practical insights and emerging evidence to guide clinicians in optimizing patient outcomes.<\/jats:p>","DOI":"10.1093\/ibd\/izaf228","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:55:57Z","timestamp":1757505357000},"page":"542-561","source":"Crossref","is-referenced-by-count":5,"title":["Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7490-7632","authenticated-orcid":false,"given":"Dimitrios","family":"Tsilimpotis","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical School, University of Patras , 26504 Patras,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-5654","authenticated-orcid":false,"given":"Georgia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical School, University of Patras , 26504 Patras,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-4125","authenticated-orcid":false,"given":"Luc","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich , 8091 Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-1954","authenticated-orcid":false,"given":"Stephan","family":"Vavricka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich , 8091 Zurich,","place":["Switzerland"]},{"name":"Zentrum f\u00fcr Gastroenterologie und Hepatologie , 8002 Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2065-3925","authenticated-orcid":false,"given":"Thomas","family":"Greuter","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich , 8091 Zurich,","place":["Switzerland"]},{"name":"Department of Gastroenterology and Hepatology, University Hospital Lausanne , 1011 Lausanne,","place":["Switzerland"]},{"name":"Department of Gastroenterology and Hepatology, GZO-Zurich Regional Health Center , 8620 Wetzikon,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich , 8091 Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-5081","authenticated-orcid":false,"given":"Michael","family":"Doulberis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich , 8091 Zurich,","place":["Switzerland"]},{"name":"Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau , 5001 Aarau,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2026100510220746800_izaf228-B1","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"2026100510220746800_izaf228-B2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"2026100510220746800_izaf228-B3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1309\/UAXMW3428PGN9HJ3","article-title":"Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease","volume":"126","author":"Goldstein","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2026100510220746800_izaf228-B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12876-024-03171-5","article-title":"Clinical features of inflammatory bowel disease unclassified: a case-control study","volume":"24","author":"Shao","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"2026100510220746800_izaf228-B5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1053\/j.gastro.2021.12.246","article-title":"Time to revisit disease classification in inflammatory bowel disease: is the current classification of inflammatory bowel disease good enough for optimal clinical management?","volume":"162","author":"Verstockt","year":"2022","journal-title":"Gastroenterology"},{"key":"2026100510220746800_izaf228-B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2050640620951905","article-title":"European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations","volume":"9","author":"Miehlke","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026100510220746800_izaf228-B7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026100510220746800_izaf228-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease\u2014epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s10620-024-08313-z","article-title":"Effect of suboptimal disease control on patient quality of life: real-world data from the observational IBD-PODCAST Canada trial","volume":"69","author":"Siffledeen","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026100510220746800_izaf228-B12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis","volume":"30","author":"Kilic","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11894-023-00913-5","article-title":"Biosimilars in IBD: what every clinician needs to know","volume":"26","author":"Angyal","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"key":"2026100510220746800_izaf228-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: targets, mechanisms and related therapies","volume":"71-72","author":"Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026100510220746800_izaf228-B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjad043","article-title":"Effectiveness and safety of vedolizumab in inflammatory bowel disease: a comprehensive meta-analysis of observational studies","volume":"17","author":"Macaluso","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2024.02.026","article-title":"Comprehensive association analyses of extraintestinal manifestations in inflammatory bowel disease","volume":"167","author":"Khrom","year":"2024","journal-title":"Gastroenterology"},{"key":"2026100510220746800_izaf228-B18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.5152\/tjg.2022.21750","article-title":"Mucocutaneous manifestations and associated factors in patients with Crohn\u2019s disease","volume":"33","author":"Kayar","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"2026100510220746800_izaf228-B19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin manifestations of inflammatory bowel disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026100510220746800_izaf228-B20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/2050640620958902","article-title":"Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes","volume":"8","author":"Jansen","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2026100510220746800_izaf228-B21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1067\/mjd.2001.114736","article-title":"Panniculitis. Part I. Mostly septal panniculitis","volume":"45","author":"Requena","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B22","doi-asserted-by":"crossref","first-page":"1234535","DOI":"10.3389\/fimmu.2023.1234535","article-title":"Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40257-022-00689-w","article-title":"Cutaneous manifestations of inflammatory bowel disease: a basic overview","volume":"23","author":"Pagani","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026100510220746800_izaf228-B24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.det.2008.05.014","article-title":"Erythema nodosum","volume":"26","author":"Requena","year":"2008","journal-title":"Dermatol Clin"},{"key":"2026100510220746800_izaf228-B25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s disease: results of the ICC registry, a nationwide prospective observational cohort study","volume":"14","author":"Biemans","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.MIB.0000442011.60285.68","article-title":"Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients","volume":"20","author":"Weizman","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B27","doi-asserted-by":"crossref","first-page":"e13600","DOI":"10.1111\/srt.13600","article-title":"Causal relationship between inflammatory bowel disease and erythema nodosum: a two-sample bidirectional Mendelian randomization study","volume":"30","author":"Zhu","year":"2024","journal-title":"Skin Res Technol"},{"key":"2026100510220746800_izaf228-B28","doi-asserted-by":"crossref","first-page":"w14599","DOI":"10.4414\/smw.2018.14599","article-title":"New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways","volume":"148","author":"Rogler","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"2026100510220746800_izaf228-B29","doi-asserted-by":"crossref","first-page":"2265028","DOI":"10.1080\/19490976.2023.2265028","article-title":"Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets","volume":"15","author":"Tie","year":"2023","journal-title":"Gut Microbes"},{"key":"2026100510220746800_izaf228-B30","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10620-019-05999-4","article-title":"Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis","volume":"65","author":"States","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2026100510220746800_izaf228-B31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MD.0b013e318187cc9c","article-title":"Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients","volume":"87","author":"Farhi","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"2026100510220746800_izaf228-B32","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/ijms25042440","article-title":"The pathophysiology and treatment of pyoderma gangrenosum-current options and new perspectives","volume":"25","author":"\u0141yko","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026100510220746800_izaf228-B33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.det.2023.08.003","article-title":"Pyoderma gangrenosum: diagnostic criteria, subtypes, systemic associations, and workup","volume":"42","author":"Zaino","year":"2024","journal-title":"Dermatol Clin"},{"key":"2026100510220746800_izaf228-B34","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3389\/fimmu.2017.01980","article-title":"Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","article-title":"Etiology and management of pyoderma gangrenosum: a comprehensive review","volume":"13","author":"Ahronowitz","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"2026100510220746800_izaf228-B36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2026100510220746800_izaf228-B37","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/biomedicines12081839","article-title":"Extraintestinal manifestations\u00a0in inflammatory bowel disease: from pathophysiology to treatment","volume":"12","author":"Faggiani","year":"2024","journal-title":"Biomedicines"},{"key":"2026100510220746800_izaf228-B38","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B39","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.3748\/wjg.v29.i32.4912","article-title":"Drug-induced entero-colitis due to interleukin-17 inhibitor use; capsule endoscopic findings and pathological characteristics: a case report","volume":"29","author":"Saito","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026100510220746800_izaf228-B40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026100510220746800_izaf228-B41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14740338.2022.2103536","article-title":"Safety and tolerability of spesolimab in patients with ulcerative colitis","volume":"22","author":"Ferrante","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2026100510220746800_izaf228-B42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14728222.2022.2084381","article-title":"IL-36: a therapeutic target for ulcerative colitis?","volume":"26","author":"Hernandez Santana","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"2026100510220746800_izaf228-B43","first-page":"481","article-title":"Ulcerative colitis diagnosed with facial pyoderma gangrenosum: a case report","volume":"121","author":"Ogata","year":"2024","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"2026100510220746800_izaf228-B44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/7750.2014.14053","article-title":"Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study","volume":"19","author":"Weizman","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"2026100510220746800_izaf228-B45","doi-asserted-by":"crossref","first-page":"otad024","DOI":"10.1093\/crocol\/otad024","article-title":"Pyoderma gangrenosum is associated with increased risk of inflammatory pouch-related complications: a retrospective cohort study","volume":"5","author":"Panganiban","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026100510220746800_izaf228-B46","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/ecco-jcc\/jjab079","article-title":"Systematic review: sweet syndrome associated with inflammatory bowel disease","volume":"15","author":"Sleiman","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13671-022-00355-8","article-title":"Neutrophilic dermatoses: a \u00adclinical update","volume":"11","author":"Weiss","year":"2022","journal-title":"Curr Dermatol Rep"},{"key":"2026100510220746800_izaf228-B48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000371879","article-title":"Severe Sweet\u2019s syndrome with elevated cutaneous Interleukin-1beta after azathioprine exposure: case report and review of the literature","volume":"230","author":"Imhof","year":"2015","journal-title":"Dermatology"},{"key":"2026100510220746800_izaf228-B49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1159\/000530519","article-title":"Sweet syndrome: a review of published cases","volume":"239","author":"Orfaly","year":"2023","journal-title":"Dermatology"},{"key":"2026100510220746800_izaf228-B50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-022-00673-4","article-title":"New practical aspects of sweet syndrome","volume":"23","author":"Joshi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026100510220746800_izaf228-B51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-2-34","article-title":"Sweet\u2019s syndrome\u2014a comprehensive review of an acute febrile neutrophilic dermatosis","volume":"2","author":"Cohen","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"2026100510220746800_izaf228-B52","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/hep.1840120609","article-title":"Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients","volume":"12","author":"Seki","year":"1990","journal-title":"Hepatology"},{"key":"2026100510220746800_izaf228-B53","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0016-5085(92)90041-V","article-title":"HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients","volume":"103","author":"Seki","year":"1992","journal-title":"Gastroenterology"},{"key":"2026100510220746800_izaf228-B54","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"2026100510220746800_izaf228-B55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100510220746800_izaf228-B56","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026100510220746800_izaf228-B57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamadermatol.2019.0891","article-title":"Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026100510220746800_izaf228-B58","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1097\/MS9.0000000000002345","article-title":"Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives","volume":"86","author":"Pandey","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"2026100510220746800_izaf228-B59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026100510220746800_izaf228-B60","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.dld.2022.10.016","article-title":"Hidradenitis suppurativa and inflammatory bowel disease in a nested case-control study","volume":"55","author":"Neri","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026100510220746800_izaf228-B61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/exd.13849","article-title":"Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017","volume":"28","author":"Shavit","year":"2019","journal-title":"Exp Dermatol"},{"key":"2026100510220746800_izaf228-B62","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/ced.13025","article-title":"Prodromal symptoms in hidradenitis suppurativa","volume":"42","author":"Ring","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"2026100510220746800_izaf228-B64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clindermatol.2023.08.016","article-title":"Assessment tools and phenotype classification for hidradenitis suppurativa","volume":"41","author":"Koerts","year":"2023","journal-title":"Clin Dermatol"},{"key":"2026100510220746800_izaf228-B65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/bjd\/ljad028","article-title":"The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review","volume":"188","author":"Mendes-Bastos","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026100510220746800_izaf228-B66","first-page":"830","article-title":"Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions","volume":"25","author":"Nazzaro","year":"2019","journal-title":"Skin Res Technol"},{"key":"2026100510220746800_izaf228-B67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jum.16351","article-title":"Update on ultrasound diagnostic criteria and new ultrasound severity and activity scorings of hidradenitis suppurativa: modified SOS-HS and US-HSA","volume":"43","author":"Wortsman","year":"2024","journal-title":"J Ultrasound Med"},{"key":"2026100510220746800_izaf228-B68","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/medicina59040801","article-title":"Hidradenitis Suppurativa and JAK Inhibitors: a review of the published literature","volume":"59","author":"Martora","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026100510220746800_izaf228-B69","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s13555-023-00935-x","article-title":"The current clinical trial landscape for hidradenitis suppurativa: a narrative review","volume":"13","author":"Hunt","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026100510220746800_izaf228-B70","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/ijd.16804","article-title":"Azathioprine in hidradenitis suppurativa with inflammatory phenotype: a case series of 11 patients","volume":"62","author":"Lopez Riquelme","year":"2023","journal-title":"Int J Dermatol"},{"key":"2026100510220746800_izaf228-B71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/der2.110","article-title":"Biologics and small molecule inhibitors for hidradenitis suppurativa","volume":"3","author":"Shih","year":"2022","journal-title":"Dermatol Rev"},{"key":"2026100510220746800_izaf228-B72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/der2.106","article-title":"Systemic nonbiologic treatments for hidradenitis suppurativa","volume":"3","author":"Greif","year":"2022","journal-title":"Dermatol Rev"},{"key":"2026100510220746800_izaf228-B73","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa\u2014Short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026100510220746800_izaf228-B74","first-page":"76","article-title":"Biologic agents in systemic dermatotherapy: cutaneous and systemic side effects","volume":"12","author":"Badavanis","year":"2017","journal-title":"Curr Drug Saf"},{"key":"2026100510220746800_izaf228-B75","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1053\/j.gastro.2023.11.102","article-title":"Association of hidradenitis suppurativa and inflammatory bowel disease: a systematic review and meta-analysis","volume":"166","author":"Polpichai","year":"2024","journal-title":"Gastroenterology"},{"key":"2026100510220746800_izaf228-B76","doi-asserted-by":"crossref","first-page":"1071616","DOI":"10.3389\/fimmu.2023.1071616","article-title":"Causal association between inflammatory bowel disease and hidradenitis suppurativa: a two-sample bidirectional Mendelian randomization study","volume":"14","author":"Bao","year":"2023","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MIB.0000000000000579","article-title":"Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease","volume":"22","author":"Janse","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B78","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10620-018-4919-5","article-title":"Risk factors for hidradenitis suppurativa in patients with inflammatory bowel disease","volume":"63","author":"Lukach","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2026100510220746800_izaf228-B79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0001-7310(17)30006-6","article-title":"Hidradenitis suppurativa and perianal Crohn disease: differential diagnosis","volume":"107 Suppl 2","author":"Bassas-Vila","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"2026100510220746800_izaf228-B80","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2026100510220746800_izaf228-B81","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","article-title":"Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis","volume":"14","author":"Alinaghi","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B82","doi-asserted-by":"crossref","first-page":"2281658","DOI":"10.1080\/07853890.2023.2281658","article-title":"Integrated analysis of Mendelian Ran\u00addomization and Bayesian colocalization reveals bidirectional causal association between inflammatory bowel disease and psoriasis","volume":"55","author":"Cai","year":"2023","journal-title":"Ann Med"},{"key":"2026100510220746800_izaf228-B83","doi-asserted-by":"crossref","first-page":"e13795","DOI":"10.1111\/srt.13795","article-title":"Mendelian randomization analysis of psoriasis and psoriatic arthritis associated with risks of ulcerative colitis","volume":"30","author":"Pan","year":"2024","journal-title":"Skin Res Technol"},{"key":"2026100510220746800_izaf228-B84","doi-asserted-by":"crossref","first-page":"847160","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving Anti-TNF therapy: systematic review with meta-analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B85","doi-asserted-by":"crossref","first-page":"e13574","DOI":"10.1111\/srt.13574","article-title":"Identification of potential crucial genes shared in psoriasis and ulcerative colitis by machine learning and integrated bioinformatics","volume":"30","author":"Zhang","year":"2024","journal-title":"Skin Res Technol"},{"key":"2026100510220746800_izaf228-B86","doi-asserted-by":"crossref","first-page":"e13536","DOI":"10.1111\/srt.13536","article-title":"Exploration of the biomarkers of comorbidity of psoriasis with inflammatory bowel disease and their association with immune infiltration","volume":"29","author":"Ding","year":"2023","journal-title":"Skin Res Technol"},{"key":"2026100510220746800_izaf228-B87","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026100510220746800_izaf228-B88","volume-title":"Evidence-Based Psoriasis. Updates in Clinical Dermatology","author":"Kimmel","year":"2018"},{"key":"2026100510220746800_izaf228-B89","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s13555-023-01060-5","article-title":"Psychosocial burden of psoriasis: a systematic literature review of depression among patients with psoriasis","volume":"13","author":"Luna","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026100510220746800_izaf228-B90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/24755303211047479","article-title":"TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors","volume":"7","author":"Hong","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2026100510220746800_izaf228-B91","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B92","doi-asserted-by":"crossref","first-page":"e13611","DOI":"10.1111\/srt.13611","article-title":"Evidence for the gut-skin axis: common genetic structures in inflammatory bowel disease and psoriasis","volume":"30","author":"Guo","year":"2024","journal-title":"Skin Res Technol"},{"key":"2026100510220746800_izaf228-B93","first-page":"282","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026100510220746800_izaf228-B94","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s13555-023-00964-6","article-title":"The relationship between rosacea and inflammatory bowel disease: a systematic review and meta-analysis","volume":"13","author":"Jun","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026100510220746800_izaf228-B95","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MIB.0000000000000644","article-title":"Rosacea in patients with ulcerative colitis and Crohn\u2019s disease: a population-based case-control study","volume":"22","author":"Spoendlin","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jaad.2023.10.003","article-title":"Association between inflammatory bowel disease and rosacea: a bidirectional two-sample Mendelian randomization study","volume":"90","author":"Shen","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B97","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1038\/s41598-023-42073-6","article-title":"Detecting potential causal relationship between inflammatory bowel disease and rosacea using bi-directional Mendelian randomization","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"2026100510220746800_izaf228-B98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaad.2017.07.055","article-title":"Evidence-based update on rosacea comorbidities and their common physiologic pathways","volume":"78","author":"Holmes","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B99","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40257-021-00595-7","article-title":"Rosacea: new concepts in classification and treatment","volume":"22","author":"van Zuuren","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2026100510220746800_izaf228-B100","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/bjd.18420","article-title":"Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel","volume":"182","author":"Schaller","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026100510220746800_izaf228-B101","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s13555-019-00322-5","article-title":"Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the national rosacea society","volume":"9","author":"Baldwin","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026100510220746800_izaf228-B102","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-024-02003-w","article-title":"Microencapsulated benzoyl peroxide for rosacea in context: a review of the current treatment landscape","volume":"84","author":"Desai","year":"2024","journal-title":"Drugs"},{"key":"2026100510220746800_izaf228-B103","doi-asserted-by":"crossref","first-page":"1403798","DOI":"10.3389\/fimmu.2024.1403798","article-title":"Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea","volume":"15","author":"Tu","year":"2024","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51 Suppl 1","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"2026100510220746800_izaf228-B105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaad.2012.11.038","article-title":"Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin","volume":"68","author":"Weinstock","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B106","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cgh.2008.02.054","article-title":"Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication","volume":"6","author":"Parodi","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B107","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s10620-018-5109-1","article-title":"Testing and treating small intestinal bacterial overgrowth reduces symptoms in patients with inflammatory bowel disease","volume":"63","author":"Cohen-Mekelburg","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2026100510220746800_izaf228-B108","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ijd.16881","article-title":"Rosacea, a rare cutaneous adverse effect of antitumor necrosis factor alpha medications: a case report and review of the literature","volume":"63","author":"Azzazi","year":"2024","journal-title":"Int J Dermatol"},{"key":"2026100510220746800_izaf228-B109","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic \u00addermatitis: a comprehensive systematic analysis and modelling study","volume":"190","author":"Tian","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026100510220746800_izaf228-B110","doi-asserted-by":"crossref","first-page":"1361005","DOI":"10.3389\/fimmu.2024.1361005","article-title":"Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches","volume":"15","author":"Afshari","year":"2024","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B111","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jdv.20291","article-title":"Langerhans cells: central players in the pathophysiology of atopic dermatitis","volume":"39","author":"Pan","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100510220746800_izaf228-B112","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaci.2015.06.029","article-title":"Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes","volume":"137","author":"Schmitt","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026100510220746800_izaf228-B113","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41385-022-00524-9","article-title":"Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation","volume":"15","author":"Trompette","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2026100510220746800_izaf228-B114","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1038\/s41598-019-41149-6","article-title":"Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture","volume":"9","author":"Reddel","year":"2019","journal-title":"Sci Rep"},{"key":"2026100510220746800_izaf228-B115","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.jaip.2024.08.052","article-title":"Atopic dermatitis (eczema) guidelines 2023: highlights","volume":"12","author":"De Benedetto","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026100510220746800_izaf228-B116","doi-asserted-by":"crossref","first-page":"127595","DOI":"10.1016\/j.micres.2023.127595","article-title":"Atopic dermatitis: pathophysiology, microbiota, and metabolome\u2014a comprehensive review","volume":"281","author":"Mohammad","year":"2024","journal-title":"Microbiol Res"},{"key":"2026100510220746800_izaf228-B117","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/jcm13061602","article-title":"The psychology of atopic dermatitis","volume":"13","author":"Courtney","year":"2024","journal-title":"J Clin Med"},{"key":"2026100510220746800_izaf228-B118","first-page":"1419","article-title":"Atopic dermatitis: disease features, therapeutic options, and a multidisciplinary approach","volume":"13","author":"Lugovic-Mihic","year":"2023","journal-title":"Life (Basel)"},{"key":"2026100510220746800_izaf228-B119","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","article-title":"Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors","volume":"25","author":"Kim","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026100510220746800_izaf228-B120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/nano12040636","article-title":"Tetrahydrocurcumin lipid nanoparticle based gel promotes penetration into deeper skin layers and alleviates atopic dermatitis in 2,4-Dinitrochlorobenzene (DNCB) mouse model","volume":"12","author":"Saini","year":"2022","journal-title":"Nanomaterials (Basel)"},{"key":"2026100510220746800_izaf228-B121","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jaad.2020.05.130","article-title":"Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"83","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B122","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/ibd\/izab240","article-title":"Association between inflammatory bowel disease and atopic dermatitis: a two-sample mendelian randomization study","volume":"28","author":"Gu","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B123","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ibd\/izab329","article-title":"Causal association between atopic dermatitis and inflammatory bowel disease: a 2-sample bidirectional mendelian randomization study","volume":"28","author":"Meisinger","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B124","doi-asserted-by":"crossref","first-page":"114027","DOI":"10.1016\/j.jpeds.2024.114027","article-title":"Atopic dermatitis in early childhood and risk of inflammatory bowel disease: a Scandinavian birth cohort study","volume":"270","author":"Lerchova","year":"2024","journal-title":"J Pediatr"},{"key":"2026100510220746800_izaf228-B125"},{"key":"2026100510220746800_izaf228-B126","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1346-8138.2007.00337.x","article-title":"Case of acne conglobata successfully treated by CO2 laser combined with topical tretinoin therapy","volume":"34","author":"Hasegawa","year":"2007","journal-title":"J Dermatol"},{"key":"2026100510220746800_izaf228-B127","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2013.6678","article-title":"Adalimumab for the treatment of refractory acne conglobata","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026100510220746800_izaf228-B128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1524-4725.1981.tb00683.x","article-title":"Surgical treatment of severe acne conglobata","volume":"7","author":"Weinrauch","year":"1981","journal-title":"J Dermatol Surg Oncol"},{"key":"2026100510220746800_izaf228-B129","doi-asserted-by":"crossref","first-page":"102986","DOI":"10.1016\/j.pdpdt.2022.102986","article-title":"A case of 5-aminolevulinic acid photodynamic therapy(ALA-PDT)combined with surgery for the treatment of acne conglobata","volume":"39","author":"Wu","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2026100510220746800_izaf228-B130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5001\/omj.2018.79","article-title":"Severe nodulocystic acne not responding to isotretinoin therapy successfully treated with oral dapsone","volume":"33","author":"Al-Kathiri","year":"2018","journal-title":"Oman Med J"},{"key":"2026100510220746800_izaf228-B131","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol"},{"key":"2026100510220746800_izaf228-B132","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/1346-8138.15676","article-title":"Various skin manifestations related to inflammatory bowel disease: a nationwide cross-sectional study on the Korean population","volume":"48","author":"Jo","year":"2021","journal-title":"J Dermatol"},{"key":"2026100510220746800_izaf228-B133","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1684\/ejd.2017.2990","article-title":"Acne conglobata induced by adalimumab","volume":"27","author":"Balakirski","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2026100510220746800_izaf228-B134","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/pde.14990","article-title":"Severe acne and its variants: exploring its natural history and heritability","volume":"39","author":"Greywal","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"2026100510220746800_izaf228-B135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/ced.12585","article-title":"Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene","volume":"40","author":"Zeeli","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"2026100510220746800_izaf228-B136","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"2026100510220746800_izaf228-B137","first-page":"e30330","article-title":"An overview of Systemic Lupus Erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"2026100510220746800_izaf228-B138","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaut.2009.09.006","article-title":"Clustering and commonalities among autoimmune diseases","volume":"33","author":"Mackay","year":"2009","journal-title":"J Autoimmun"},{"key":"2026100510220746800_izaf228-B139","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1186\/s12864-024-10787-0","article-title":"Investigating the shared genetic basis of inflammatory bowel disease and systemic lupus erythematosus using genetic overlap analysis","volume":"25","author":"Yuan","year":"2024","journal-title":"BMC Genomics"},{"key":"2026100510220746800_izaf228-B140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous Involvement in Systemic Lupus Erythematosus: a review for the rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J Rheumatol"},{"key":"2026100510220746800_izaf228-B141","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.abd.2022.09.005","article-title":"Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects","volume":"98","author":"Vale","year":"2023","journal-title":"An Bras Dermatol"},{"key":"2026100510220746800_izaf228-B142","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.3390\/ijms231810706","article-title":"Modulation of immune cells as a therapy for cutaneous lupus erythematosus","volume":"23","author":"Soto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026100510220746800_izaf228-B143","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.autrev.2016.07.027","article-title":"Does inflammatory bowel disease coexist with systemic lupus erythematosus?","volume":"15","author":"Shor","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2026100510220746800_izaf228-B144","doi-asserted-by":"crossref","first-page":"1199896","DOI":"10.3389\/fimmu.2023.1199896","article-title":"Association between systemic lupus erythematosus and inflammatory bowel disease in European and East Asian populations: a two-sample Mendelian randomization study","volume":"14","author":"Xie","year":"2023","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B145","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100510220746800_izaf228-B146","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1002\/ski2.317","article-title":"Prevalence and burden of vitiligo in Africa, the Middle East and Latin America","volume":"4","author":"Al Hammadi","year":"2024","journal-title":"Skin Health Dis"},{"key":"2026100510220746800_izaf228-B147","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2016.08.022","article-title":"Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study","volume":"76","author":"Kim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B148","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417306","article-title":"Vitiligo: pathogenesis and new and emerging treatments","volume":"24","author":"Perez-Bootello","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026100510220746800_izaf228-B149","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/CCID.S459070","article-title":"Endoplasmic reticulum dysfunction: an emerging mechanism of vitiligo pathogenesis","volume":"17","author":"Xie","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026100510220746800_izaf228-B150","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1002\/iid3.1341","article-title":"Mechanism of desuccinylation of G6PD mediated by SIRT7 to promote vitiligo disease progression","volume":"12","author":"Yang","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2026100510220746800_izaf228-B151","doi-asserted-by":"crossref","first-page":"17562848221115312","DOI":"10.1177\/17562848221115312","article-title":"Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations","volume":"15","author":"Bezzio","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2026100510220746800_izaf228-B152","first-page":"e29307","article-title":"Vitiligo: a narrative review","volume":"14","author":"Joge","year":"2022","journal-title":"Cureus"},{"key":"2026100510220746800_izaf228-B153","first-page":"e45030","article-title":"Unveiling the unseen struggles: a comprehensive review of Vitiligo\u2019s psychological, social, and quality of life impacts","volume":"15","author":"Salama","year":"2023","journal-title":"Cureus"},{"key":"2026100510220746800_izaf228-B154","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task Force-Part 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100510220746800_izaf228-B155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"2026100510220746800_izaf228-B156","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"2026100510220746800_izaf228-B157","doi-asserted-by":"crossref","first-page":"2382774","DOI":"10.1080\/19490976.2024.2382774","article-title":"Current insights on gut microbiome and chronic urticaria: progress in the pathogenesis and opportunities for novel therapeutic approaches","volume":"16","author":"Cai","year":"2024","journal-title":"Gut Microbes"},{"key":"2026100510220746800_izaf228-B158","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3748\/wjg.v18.i34.4787","article-title":"Angioedema associated with Crohn\u2019s disease: response to biologics","volume":"18","author":"Habal","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2026100510220746800_izaf228-B159","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/ijd.14000","article-title":"Associations of chronic urticaria with atopic and autoimmune comorbidities: a nationwide population-based study","volume":"57","author":"Chiu","year":"2018","journal-title":"Int J Dermatol"},{"key":"2026100510220746800_izaf228-B160","doi-asserted-by":"crossref","first-page":"100533","DOI":"10.1016\/j.waojou.2021.100533","article-title":"The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management","volume":"14","author":"Sanchez-Borges","year":"2021","journal-title":"World Allergy Organ J"},{"key":"2026100510220746800_izaf228-B161","doi-asserted-by":"crossref","first-page":"1280135","DOI":"10.3389\/fimmu.2023.1280135","article-title":"Common autoimmune diseases and urticaria: the causal relationship from a bidirectional two-sample Mendelian randomization study","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"2026100510220746800_izaf228-B162","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.mayocp.2014.04.015","article-title":"Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota","volume":"89","author":"Arora","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2026100510220746800_izaf228-B163","doi-asserted-by":"crossref","first-page":"23247096231181865","DOI":"10.1177\/23247096231181865","article-title":"Leukocytoclastic vasculitis in a patient with Crohn disease: a case report","volume":"11","author":"Bugada","year":"2023","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2026100510220746800_izaf228-B164","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11739-021-02688-x","article-title":"Diagnosis and management of leukocytoclastic vasculitis","volume":"16","author":"Fraticelli","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2026100510220746800_izaf228-B165","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/jcm11030739","article-title":"Clinical manifestations of leukocytoclastic vasculitis, treatment, and outcome in patients with ulcerative colitis: a systematic review of the literature","volume":"11","author":"Pantic","year":"2022","journal-title":"J Clin Med"},{"key":"2026100510220746800_izaf228-B166","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2023.04.055","article-title":"Epidemiology and diagnostic classification of adults presenting with an initial episode of leukocytoclastic vasculitis: a multicenter review of 440 patients","volume":"89","author":"Walls","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026100510220746800_izaf228-B167","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/jcm12093165","article-title":"Leukocytoclastic vasculitis secondary to anti-tumor necrosis factor therapy in inflammatory bowel diseases: a multicenter retrospective cohort study","volume":"12","author":"Parra","year":"2023","journal-title":"J Clin Med"},{"key":"2026100510220746800_izaf228-B168","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1159\/000512747","article-title":"The association between alopecia and inflammatory bowel disease: a systematic review and meta-analysis","volume":"237","author":"Maghfour","year":"2021","journal-title":"Dermatology"},{"key":"2026100510220746800_izaf228-B169","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamadermatol.2023.0016","article-title":"Overall and racial and ethnic subgroup prevalences of alopecia areata, alopecia totalis, and alopecia universalis","volume":"159","author":"Sy","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026100510220746800_izaf228-B170","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/genes14071362","article-title":"Clinical and genetic aspects of alopecia areata: a cutting edge review","volume":"14","author":"Ho","year":"2023","journal-title":"Genes (Basel)"},{"key":"2026100510220746800_izaf228-B171","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: a multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J Autoimmun"},{"key":"2026100510220746800_izaf228-B172","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.3390\/jcm13113292","article-title":"Alopecia areata of the nails: diagnosis and management","volume":"13","author":"Pelzer","year":"2024","journal-title":"J Clin Med"},{"key":"2026100510220746800_izaf228-B173","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10238-020-00673-w","article-title":"Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options","volume":"21","author":"Sterkens","year":"2021","journal-title":"Clin Exp Med"},{"key":"2026100510220746800_izaf228-B174","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/jdv.18810","article-title":"Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors","volume":"37","author":"Gupta","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100510220746800_izaf228-B175","doi-asserted-by":"crossref","first-page":"2050313X231160914","DOI":"10.1177\/2050313X231160914","article-title":"Successful treatment of concomitant alopecia universalis and Crohn\u2019s disease with upadacitinib: a case report","volume":"11","author":"Johnston","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"2026100510220746800_izaf228-B176","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3390\/ijms25041984","article-title":"The role of the gut microbiome and microbial dysbiosis in common skin diseases","volume":"25","author":"Rygu\u0142a","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026100510220746800_izaf228-B177","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100510220746800_izaf228-B178","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/MEG.0000000000001917","article-title":"Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy","volume":"33","author":"Nigam","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B179","first-page":"836","article-title":"New-onset blepharitis and Anti-TNF-Alpha therapy in patients with Crohn\u2019s disease: a case series and literature review","volume":"25","author":"Weintraub","year":"2023","journal-title":"Isr Med Assoc J"},{"key":"2026100510220746800_izaf228-B180","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/imj.15859","article-title":"Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm","volume":"53","author":"Au","year":"2023","journal-title":"Intern Med J"},{"key":"2026100510220746800_izaf228-B181","first-page":"889","article-title":"Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFalpha agents","volume":"10","author":"Dalle Vedove","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026100510220746800_izaf228-B182","first-page":"e69219","article-title":"Pyoderma gangrenosum in an ulcerative colitis patient on vedolizumab","volume":"16","author":"Choe","year":"2024","journal-title":"Cureus"},{"key":"2026100510220746800_izaf228-B183","doi-asserted-by":"crossref","first-page":"530","DOI":"10.17235\/reed.2018.5603\/2018","article-title":"Sweet syndrome after treatment with vedolizumab in a patient with Crohn\u2019s disease","volume":"110","author":"Martinez Andres","year":"2018","journal-title":"Rev Esp Enferm Dig"},{"key":"2026100510220746800_izaf228-B184","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/1346-8138.16318","article-title":"Psoriasiform dermatitis in a girl with ulcerative colitis receiving vedolizumab","volume":"49","author":"Tsuchiya","year":"2022","journal-title":"J Dermatol"},{"key":"2026100510220746800_izaf228-B185","doi-asserted-by":"crossref","first-page":"17562848241299564","DOI":"10.1177\/17562848241299564","article-title":"Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12\/23 and anti-IL-23 antibodies","volume":"17","author":"Bezzio","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"2026100510220746800_izaf228-B186","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1111\/jdv.16293","article-title":"Baricitinib-induced paradoxical psoriasis","volume":"34","author":"Di Domizio","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100510220746800_izaf228-B187","first-page":"A122","article-title":"A. 4CPS-183 Multicentre study: evaluation of the effectiveness and safety of upadacitinib in inflammatory bowel disease","volume":"32","author":"G\u00f3mez Balazote","year":"2025","journal-title":"Eur J Hosp Pharm"},{"key":"2026100510220746800_izaf228-B188","first-page":"88","article-title":"Paradoxical reactions to biologicals in chronic inflammatory systemic diseases","volume":"119","author":"Kremenevski","year":"2022","journal-title":"Dtsch Arztebl Int"},{"key":"2026100510220746800_izaf228-B189","doi-asserted-by":"crossref","first-page":"1064537","DOI":"10.3389\/fcimb.2022.1064537","article-title":"Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy","volume":"12","author":"Reiss","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026100510220746800_izaf228-B190","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by Anti-TNFalpha treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026100510220746800_izaf228-B191","doi-asserted-by":"crossref","first-page":"2133533","DOI":"10.1080\/09546634.2022.2133533","article-title":"Systematic review of TNFalpha-induced paradoxical psoriasis: treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients","volume":"34","author":"Revankar","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026100510220746800_izaf228-B192","first-page":"176","article-title":"Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab","volume":"116","author":"Dai","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"2026100510220746800_izaf228-B193","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40257-019-00483-1","article-title":"Herpes zoster presentation, management, and prevention: a modern case-based review","volume":"21","author":"Rosamilia","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026100510220746800_izaf228-B194","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/ijdvl.IJDVL_1021_16","article-title":"Epidemiology, treatment and prevention of herpes zoster: a comprehensive review","volume":"84","author":"Koshy","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026100510220746800_izaf228-B195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"2026100510220746800_izaf228-B196","doi-asserted-by":"crossref","first-page":"e26863","DOI":"10.1097\/MD.0000000000026863","article-title":"The incidence rate of herpes zoster in inflammatory bowel disease: a meta-analysis of cohort studies","volume":"100","author":"Lai","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026100510220746800_izaf228-B197","first-page":"jjaa132","article-title":"Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know","volume":"16","author":"Schreiner","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026100510220746800_izaf228-B198","doi-asserted-by":"crossref","first-page":"goad016","DOI":"10.1093\/gastro\/goad016","article-title":"Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn\u2019s disease in the USA","volume":"11","author":"Singer","year":"2023","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"2026100510220746800_izaf228-B199","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026100510220746800_izaf228-B200","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100510220746800_izaf228-B201","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cgh.2024.09.022","article-title":"Patients with inflammatory bowel disease are at increased risk for complications of Herpes Zoster","volume":"23","author":"Caldera","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B202","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1128\/JCM.38.7.2568-2573.2000","article-title":"Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence","volume":"38","author":"de Jong","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2026100510220746800_izaf228-B203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/v10110609","article-title":"Clinical features of varicella-zoster virus infection","volume":"10","author":"Kennedy","year":"2018","journal-title":"Viruses"},{"key":"2026100510220746800_izaf228-B204","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ibd\/izy232","article-title":"Frequency of Herpes Zoster vaccination among inflammatory bowel disease patients","volume":"25","author":"Khan","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026100510220746800_izaf228-B205","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026100510220746800_izaf228-B206","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S2468-1253(24)00429-1","article-title":"Widening access to recombinant zoster vaccination in IBD","volume":"10","author":"Alexander","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100510220746800_izaf228-B207","doi-asserted-by":"crossref","first-page":"e00009","DOI":"10.14309\/ctg.0000000000000009","article-title":"Modulatory effects of pregnancy on inflammatory bowel disease","volume":"10","author":"van der Giessen","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"2026100510220746800_izaf228-B208","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0028-1109423","article-title":"Pregnancy-associated Sweet\u2019s syndrome in an acute episode of ulcerative colitis","volume":"47","author":"Best","year":"2009","journal-title":"Z Gastroenterol"},{"key":"2026100510220746800_izaf228-B209","doi-asserted-by":"crossref","first-page":"e2023S109","DOI":"10.1590\/1806-9282.2023s109","article-title":"Update on specific dermatoses of pregnancy","volume":"69","author":"Carvalho","year":"2023","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"2026100510220746800_izaf228-B210","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-4362.1998.00316.x","article-title":"Erythema nodosum and associated diseases. A study of 129 cases","volume":"37","author":"Cribier","year":"1998","journal-title":"Int J Dermatol"},{"key":"2026100510220746800_izaf228-B211","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100670050159","article-title":"Erythema nodosum: the underlying conditions","volume":"19","author":"Psychos","year":"2000","journal-title":"Clin Rheumatol"},{"key":"2026100510220746800_izaf228-B212","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ijd.17474","article-title":"Pregnancy-associated pyoderma gangrenosum: a systematic review","volume":"64","author":"Tan","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026100510220746800_izaf228-B213","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-024-01563-9","article-title":"Conception, pregnancy and inflammatory bowel disease-Current concepts for the practising clinician","author":"Liu","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"2026100510220746800_izaf228-B214","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12884-024-06443-w","article-title":"Anti-tumor necrosis factor-alpha therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"2026100510220746800_izaf228-B215","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jaci.2021.07.005","article-title":"Safety of anti-TNF agents in pregnancy","volume":"148","author":"De Felice","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/3\/542\/64926211\/izaf228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/3\/542\/64926211\/izaf228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:22:39Z","timestamp":1791210159000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/3\/542\/8301081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":215,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf228","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,23]]}}}